UNSPSC 51391702: Adrenalone

This classification denotes an adrenergic agent with the molecular formula C9H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EGU41QL329, chemically known as 3,4-dihydroxy-alpha-methylaminoacetophenone but generally known as adrenalone, which bears US NIH Compound Identifier 7436. Adrenalone comes in forms base and hydrochloride. European Medicines Agency schedules Adrenalone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05279MIG. The term ADRENALONE is an International Non-Proprietary Name.

UNSPSC 51391702 Adrenalone is a Commodity code that state and local governments use to classify emergency medical supplies and pharmaceutical products related to opioid response and overdose intervention. Based on recent solicitations, the work actually being bought under this code centers on naloxone (a reversal agent for opioid overdose) and associated drug deactivation systems procured for community health and emergency response programs. Seminole County, Florida, for example, recently issued an IFB seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to a county health facility and a two-year initial term with one-year renewal option. Issuing bodies under this code include county health departments and state health and human services commissions; the mix reflects jurisdictions managing opioid-crisis response and pharmacy benefit programs rather than a broad cross-section of state and local procurement activity.

Geographic activity is concentrated in Florida and Texas based on recent postings. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, requiring electronic bid submission through the county e-Procurement Portal and compliance with E-Verify, drug-free workplace certification, and standard insurance requirements. The Texas Health and Human Services Commission posted an exploratory Request for Information (RFI HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—a preliminary market-intelligence phase rather than a binding solicitation, designed to inform future procurement strategy for direct pharmacy-to-manufacturer relationships serving state employee health plans. Neither opportunity specifies explicit set-aside designations for disadvantaged enterprises.